Alendronate, a bisphosphonate compound, is used to treat osteoporosis by inhibiting bone resorption. However, oral consumption of Alendronate can cause severe gastrointestinal side effects, such as heartburn, difficulty swallowing, constipation or diarrhea, flatulence, and esophageal irritation or pain. To overcome this problem, an injectable sustained-release formulation of alendronate based on lipid liquid crystal (LLC) using phosphatidylcholine (PC), sorbitan monooleate (SMO), glycerol di-oleate (GDO), and N-methyl-2-pyrrolidone (NMP) or ethanol solvents was recommended. This compound was added as a base to one side of a coupling syringe, while alendronate powder was added to the other. After combining the two syringes, the resulting formulations were transferred into tubes containing PBS for in-vitro evaluation. In formulations containing ethanol, the cumulative percentage of drug release, water content, and degradation were higher than in those with NMP. Furthermore, LLC gel formulations with ethanol solvent had lower viscosity and a cubic structure, whereas LLC containing NMP had a hexagonal structure, indicating slower and longer release of alendronate in LLC-NMP formulations. In-vivo evaluations of subcutaneous injections of alendronate based on LLC formulation in rats with ovariectomy-induced osteoporosis showed significant advancements in osteogenesis markers, including RUNX2, OPG, VEGF, and Type 1 Collagen, according to Western blot analysis. These finding highlight alendronate's potential not only as a bone resorption inhibitor but also as a bone formation stimulator. Additionally, histopathology results revealed no osteoclast activity or osteoarthritis reactions in the LLC formulation group. Hence, an injectable LLC formulation containing PC, SMO and NMP could be a suitable option for developing a sustained-release LLC formulation of alendronate for osteoporosis treatment.
Read full abstract